ivWatch Announces Federal Distribution Agreement with Marathon Medical Corp.

ivWatch, LLC, the IV safety company, today announced it has entered into a distribution agreement with Marathon Medical Corp., a medical supply distribution company and service-disabled veteran-owned small business (SDVOSB) focused on providing a range of medical products to Federal healthcare agencies. ivWatch’s patient monitoring technology helps protect patients from unpredictable IV complications with early IV infiltration and extravasation detection.

Under the terms of the multi-year agreement, Marathon Medical will distribute the ivWatch patient monitoring system in the United States to VA hospitals and clinics, Indian Health Service hospitals and clinics, and other Federal agencies. In conjunction with the partnership, ivWatch products will be added to Marathon’s FSS/GSA contracts, significantly increasing visibility, and providing direct access to ivWatch technology for advancing IV therapy.

With over 30 clinical studies and more than 20 years of research and development completed, ivWatch products use a predictive algorithm combined with multi-spectral light to identify extravasations at the earliest onset of fluid leaking outside of the vein. Every extravasation is a medication dosing error and can lead to severe outcomes such as nerve damage, scarring, skin necrosis, and even amputation, in the most serious instances. ivWatch and Marathon Medical will work in partnership to provide clinical vascular access education services, product evaluations for facilities to understand how the technology seamlessly integrates into their workflow, and product implementation support.

ivWatch’s president and CEO Gary Warren was particularly passionate about securing this partnership as a former 14-year federal employee of NASA and someone whose family history is deeply rooted in the military, with multiple generations having served – including three of his sons who served or are currently serving in the Navy.

“ivWatch and Marathon Medical share the same belief in the importance of standing up, speaking up and fighting for better patient safety – and that determination combined with our shared employee cultures of empathy and selflessness define our partnership,” said Warren. “I knew from the moment I walked into their headquarters and met John and his team that our collective future would involve taking immediate action in our communities – mobilizing our veterans and frontline workers and making a positive difference in IV therapy outcomes. Every day we are on a mission to end this silent extravasation epidemic and empower patients, many of whom have already endured extensive pain and hardship.”

Marathon Medical was founded in 2002 by Vietnam-era veteran John St. Leger and is committed to the patient first and foremost. The company, whose manufacturing partners include Abbott, Braun Medical, Medtronic, PDI and others, remembers, honors, and gives back to the community it serves by donating to the Navy SEAL Foundation, American Military Family, and Tails of Valor. 

Noted St. Leger, “We’re passionate about helping keep our US military, Federal employee, and Native American communities healthy and safe, and ivWatch aligns perfectly with that mission. We’re thrilled to partner with and support a fellow small business to improve IV safety through advanced technology. Together, we look forward to drastically changing the experience and outcomes of patients and improving clinical practices for frontline workers.”

To learn more about the ivWatch patient monitoring system, visit

Recent News


ATCC Announces Award from NIAID to Consolidate its BEI Resources and NIH HIV Reagent Programs

ATCC, the world’s premier biological materials management and standards organization, today announced a seven-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to continue the management of the BEI Resources Program. NIAID has made an initial award of over $21.5 million, with further funding


Acclinate Collaborates with Merck to Increase Clinical Trial Diversity

Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to help increase participation by members of the Black/African American community in Merck’s oncology clinical studies. “We’re proud to be working with Merck because being a champion for health equity through inclusive research


cultivate(MD) Capital Funds LP Announces Investment into Nanochon

cultivate(MD) Capital Funds LP, funds that are focused on investments into early-stage medical device companies with innovative technologies, announced today that they have made a significant investment into Nanochon, a Washington, D.C.—based regenerative cartilage innovator. Nanochon develops solutions utilized by sports medicine physicians to treat active patients requiring cartilage restoration.  Nanochon’s Chondrograft™ replaces lost or damaged